CSP Exam Oncology 2026 with all Correct & 100% Verified
Answers |Latest Version |Already Graded A+
imatinib ✔Correct Answer-Gleevec (tyrosine kinase inhibitor)
acute lymphoblastic leukemia
ponatinib ✔Correct Answer-Iclusig
Tyrosine kinase inhibitor
acute lymphoblastic leukemia
dasatinib ✔Correct Answer-Sprycel
TKI
acute lymphoblastic leukemia
glasdegib ✔Correct Answer-Daurismo
hedgehog pathway inhibitor
acute myeloid leukemia
enasidenib ✔Correct Answer-Idhifa
IDH2 inhibitor
acute myeloid leukemia
azacitidine ✔Correct Answer-Onureg
interferes with nucleic acid metabolism
acute myeloid leukemia
midostaurin ✔Correct Answer-Rydapt
tyrosine kinase inhibitor that inhibits FLT3 mutant kinases
acute myeloid leukemia
thioguanine ✔Correct Answer-Tabloid
DNA (purine nucleotides) synthesis inhibitor
acute myeloid leukemia
ivosidenib ✔Correct Answer-Tibsovo
IDH1 inhibitor of R132 mutants
AML
quizartinib ✔Correct Answer-Vanflyta
small molecule receptor TKI FLT3
AML
, venetoclax ✔Correct Answer-Venclexta
blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death
of CLL cells
AML
gilteritinib ✔Correct Answer-Xospata
TKI (FLT3)
AML
lomustine ✔Correct Answer-Gleostine (alkylating agent)
brain tumors
eflornithine ✔Correct Answer-Iwilfin
ODC enzyme inhibitor
neuroblastoma
temozolomide ✔Correct Answer-Temodar (alkylating agent)
glioblastoma
tovorafenib ✔Correct Answer-Ojemda
RAF kinase inhibitor of mutant BRAF V600E, wtBRAF, wtCRAF kinases
everolimus ✔Correct Answer-Afinitor
mTOR inhibitor
HR+/HER2- breast cancer in combo with exemestane
palbociclib ✔Correct Answer-Ibrance
CDK4/6 inhibitor
HR+/HER2- metastatic breast cancer in combo with fulvestrant
HR+/HER2- metastatic breast cancer in postmenopausal women or men in combo w/ AI
ribociclib ✔Correct Answer-Kisqali
CDK4/6 inhibitor
HR+/HER2- metastatic breast cancer in combo w/ AI
HR+/HER2- metastatic breast cancer in postmenopausal women or men in combo w/ fulvestrant
olaparib ✔Correct Answer-Lynparza (PARP inhibitor)
breast cancer (early or metastatic) HER2-, BRCA mutation+
ovarian cancer
neratinib ✔Correct Answer-Nerlynx
Tyrosine kinase inhibitor/EGFR inhibitor
early HER2+ breast cancer
Answers |Latest Version |Already Graded A+
imatinib ✔Correct Answer-Gleevec (tyrosine kinase inhibitor)
acute lymphoblastic leukemia
ponatinib ✔Correct Answer-Iclusig
Tyrosine kinase inhibitor
acute lymphoblastic leukemia
dasatinib ✔Correct Answer-Sprycel
TKI
acute lymphoblastic leukemia
glasdegib ✔Correct Answer-Daurismo
hedgehog pathway inhibitor
acute myeloid leukemia
enasidenib ✔Correct Answer-Idhifa
IDH2 inhibitor
acute myeloid leukemia
azacitidine ✔Correct Answer-Onureg
interferes with nucleic acid metabolism
acute myeloid leukemia
midostaurin ✔Correct Answer-Rydapt
tyrosine kinase inhibitor that inhibits FLT3 mutant kinases
acute myeloid leukemia
thioguanine ✔Correct Answer-Tabloid
DNA (purine nucleotides) synthesis inhibitor
acute myeloid leukemia
ivosidenib ✔Correct Answer-Tibsovo
IDH1 inhibitor of R132 mutants
AML
quizartinib ✔Correct Answer-Vanflyta
small molecule receptor TKI FLT3
AML
, venetoclax ✔Correct Answer-Venclexta
blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death
of CLL cells
AML
gilteritinib ✔Correct Answer-Xospata
TKI (FLT3)
AML
lomustine ✔Correct Answer-Gleostine (alkylating agent)
brain tumors
eflornithine ✔Correct Answer-Iwilfin
ODC enzyme inhibitor
neuroblastoma
temozolomide ✔Correct Answer-Temodar (alkylating agent)
glioblastoma
tovorafenib ✔Correct Answer-Ojemda
RAF kinase inhibitor of mutant BRAF V600E, wtBRAF, wtCRAF kinases
everolimus ✔Correct Answer-Afinitor
mTOR inhibitor
HR+/HER2- breast cancer in combo with exemestane
palbociclib ✔Correct Answer-Ibrance
CDK4/6 inhibitor
HR+/HER2- metastatic breast cancer in combo with fulvestrant
HR+/HER2- metastatic breast cancer in postmenopausal women or men in combo w/ AI
ribociclib ✔Correct Answer-Kisqali
CDK4/6 inhibitor
HR+/HER2- metastatic breast cancer in combo w/ AI
HR+/HER2- metastatic breast cancer in postmenopausal women or men in combo w/ fulvestrant
olaparib ✔Correct Answer-Lynparza (PARP inhibitor)
breast cancer (early or metastatic) HER2-, BRCA mutation+
ovarian cancer
neratinib ✔Correct Answer-Nerlynx
Tyrosine kinase inhibitor/EGFR inhibitor
early HER2+ breast cancer